Related Experiment Video
Updated: Jun 16, 2026

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Age-Stratified ED9 5 of Remimazolam Tosilate for Moderate Sedation in Pediatric Patients: A Biased Coin Design Study
Bingqing Zhu1, Wenjun Meng1, Kunyun Pan1
1Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
Insights
This study determined age-specific effective doses of remimazolam tosilate for moderate sedation in children. Toddlers required higher doses, and closer monitoring for bradycardia is advised.
Area of Science:
- Pediatric Anesthesiology
- Pharmacology
- Clinical Trials
Background:
- Pediatric sedation presents challenges due to age-related physiological differences.
- Establishing safe and effective sedative doses for children is crucial.
Purpose of the Study:
- To determine the age-stratified 95% effective dose (ED95) of remimazolam tosilate for moderate sedation in pediatric patients.
- To identify age-specific dosing guidelines for remimazolam tosilate in children aged 1-12 years.
Main Methods:
- A biased coin design up-and-down sequential method was used to determine the ED95 in three pediatric age groups (toddlers, preschoolers, school-aged children).
- Sedation success was defined as a Modified Observer's Assessment of Alertness and Sedation (MOAA/S) score ≤ 3.
- Doses were adjusted based on patient response, and perioperative variables and adverse events were monitored.
Main Results:
- The estimated ED95 of remimazolam tosilate was 0.415 mg·kg⁻¹ in toddlers, 0.389 mg·kg⁻¹ in preschoolers, and 0.362 mg·kg⁻¹ in school-aged children.
- Toddlers exhibited the longest median wake-up time (32.5 min).
- Adverse events were infrequent, with bradycardia and oxygen desaturation observed in 5.8% of patients.
Conclusions:
- Age-specific ED95 reference doses for remimazolam tosilate in pediatric moderate sedation were established.
- While remimazolam has a favorable safety profile, individualized dose titration is essential.
- Particular attention and closer monitoring are warranted for toddlers due to a higher incidence of bradycardia.
Background:
Providing safe sedation in pediatric patients remains challenging because of age-dependent physiological variations. This study aimed to identify the age-stratified 95% effective dose (ED95) of remimazolam tosilate for achieving moderate sedation in children.
Methods:
This study enrolled children aged 1-12 years with ASA physical status I-II scheduled for elective surgery. Participants were stratified into three age groups: toddlers (1-3 years), preschoolers (3-6 years), and school-aged children (6-12 years), with 40 patients in each group. The initial dose of remimazolam tosilate was 0.2 mg·kg-1, with subsequent 0.05 mg·kg-1 adjustments using a biased coin design up-and-down sequential method based on patient response. Sedation depth was evaluated using the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale. An MOAA/S score ≤ 3 at 3 minutes after drug administration was defined as successful sedation. ED9 5 values were estimated using isotonic regression. Perioperative variables, including sedation onset time, operation time, total anesthesia time, and wake-up time, were recorded. Adverse events, including hypotension, bradycardia, and oxygen desaturation, were monitored during the observation period.
Results:
Of the 142 children screened, 120 completed the study. The estimated ED9 5 (95% confidence interval) of remimazolam tosilate was 0.415 mg·kg-1 (0.311-0.437) in toddlers, 0.389 mg·kg-1 (0.258-0.440) in preschoolers, and 0.362 mg·kg-1 (0.228-0.396) in school-aged children. Toddlers had the longest median wake-up time (32.5 min; IQR: 25.3-40.8). Hypotension was reported in 0.8% of patients (n=1), whereas bradycardia and oxygen desaturation were each observed in 5.8% of patients (n=7).
Conclusion:
This study establishes age-specific ED9 5 reference doses of remimazolam tosilate for moderate sedation in children. Although remimazolam demonstrated an overall favorable safety profile, individualized dose titration remains essential, particularly given the 17.5% incidence of bradycardia observed in toddlers, which warrants closer monitoring.
Trial Registration:
Chinese Clinical Trial Registry (ChiCTR2300075986).
Related Concept Videos
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Parenteral Anesthetics: Overview
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Sedatives and Hypnotics Drugs: Barbiturates
Stages of General Anesthesia